康宁杰瑞制药(09966.HK)指疗法获美国FDA授予孤儿药资格
康宁杰瑞制药(09966.HK)公布,全资附属江苏康宁杰瑞生物制药开发的重组人源化抗HER2双特异性抗体KN026及重组人源化PDL1/CTLA-4双特异性抗体KN046的联合疗法,获美国食品药品监督管理局(FDA)授予孤儿药资格,用於治疗胃癌及胃食管结合部癌。
公司表示,是次为公司的第三个ODD。早前於2020年1月及2020年9月,由公司开发的重组人源化单域抗体KN035及KN046分别获美国FDA授予ODD,用於治疗胆道癌及胸腺上皮肿瘤。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.